Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
36
CVAC Quote, Financials, Valuation and Earnings
Last price:
$4.66
Seasonality move
:
-15.44%
Day range:
$4.66 - $4.66
52-week range:
$2.48 - $5.72
Dividend yield:
0%
P/E ratio:
6.52x
P/S ratio:
12.94x
P/B ratio:
1.03x
Volume:
--
Avg. volume:
--
1-year change:
41.64%
Market cap:
$1B
Revenue:
$578.9M
EPS (TTM):
$0.71
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CVAC
CureVac NV
|
$15.4M | -$0.11 | 0.04% | -32.36% | $5.31 |
|
BAYRY
Bayer AG
|
$13.3B | $0.16 | 11.17% | 16.01% | $13.91 |
|
BNTX
BioNTech SE
|
$963.1M | -$0.10 | 93.93% | -31.18% | $139.76 |
|
IFRX
InflaRx NV
|
$30.9K | -$0.17 | -74.55% | -70.4% | $10.46 |
|
IMTX
Immatics NV
|
$10.9M | -$0.47 | -81.87% | -704.25% | $19.13 |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CVAC
CureVac NV
|
$4.66 | $5.31 | $1B | 6.52x | $0.00 | 0% | 12.94x |
|
BAYRY
Bayer AG
|
$13.28 | $13.91 | $52.2B | -- | $0.03 | 0.24% | 1.03x |
|
BNTX
BioNTech SE
|
$110.42 | $139.76 | $27.7B | 191.55x | $0.00 | 0% | 7.51x |
|
IFRX
InflaRx NV
|
$0.87 | $10.46 | $59.1M | -- | $0.00 | 0% | 269.55x |
|
IMTX
Immatics NV
|
$10.30 | $19.13 | $1.3B | 42.21x | $0.00 | 0% | 13.76x |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CVAC
CureVac NV
|
3.87% | 2.704 | 3.39% | 1.84x |
|
BAYRY
Bayer AG
|
57.27% | -0.191 | 142.34% | 0.55x |
|
BNTX
BioNTech SE
|
1.31% | 1.308 | 1.22% | 6.78x |
|
IFRX
InflaRx NV
|
2.1% | -0.262 | 1.26% | 2.34x |
|
IMTX
Immatics NV
|
3.78% | 2.067 | 1.86% | 6.97x |
|
MDGEF
Medigene AG
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CVAC
CureVac NV
|
$57.9M | -$11.6M | 19.52% | 20.55% | -18.33% | $31.6M |
|
BAYRY
Bayer AG
|
$6.3B | $655.6M | -0.4% | -0.91% | 5.81% | $616.1M |
|
BNTX
BioNTech SE
|
$1.6B | $743.4M | -2.96% | -3.01% | 41.89% | $785.5M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
IMTX
Immatics NV
|
-- | -$63.9M | -24.18% | -25.21% | -1053.82% | -$56.2M |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | -- | -- |
CureVac NV vs. Competitors
-
Which has Higher Returns CVAC or BAYRY?
Bayer AG has a net margin of -5832.47% compared to CureVac NV's net margin of -9.93%. CureVac NV's return on equity of 20.55% beat Bayer AG's return on equity of -0.91%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV91.57% $1.41 $1.1B BAYRYBayer AG55.41% -$0.29 $81.5B -
What do Analysts Say About CVAC or BAYRY?
CureVac NV has a consensus price target of $5.31, signalling upside risk potential of 14.28%. On the other hand Bayer AG has an analysts' consensus of $13.91 which suggests that it could grow by 4.76%. Given that CureVac NV has higher upside potential than Bayer AG, analysts believe CureVac NV is more attractive than Bayer AG.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV1 3 0 BAYRYBayer AG1 1 0 -
Is CVAC or BAYRY More Risky?
CureVac NV has a beta of 1.877, which suggesting that the stock is 87.704% more volatile than S&P 500. In comparison Bayer AG has a beta of 0.677, suggesting its less volatile than the S&P 500 by 32.328%.
-
Which is a Better Dividend Stock CVAC or BAYRY?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bayer AG offers a yield of 0.24% to investors and pays a quarterly dividend of $0.03 per share. CureVac NV pays -- of its earnings as a dividend. Bayer AG pays out 4.24% of its earnings as a dividend. Bayer AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CVAC or BAYRY?
CureVac NV quarterly revenues are $63.3M, which are smaller than Bayer AG quarterly revenues of $11.3B. CureVac NV's net income of $319.3M is higher than Bayer AG's net income of -$1.1B. Notably, CureVac NV's price-to-earnings ratio is 6.52x while Bayer AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 12.94x versus 1.03x for Bayer AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV12.94x 6.52x $63.3M $319.3M BAYRYBayer AG1.03x -- $11.3B -$1.1B
-
Which has Higher Returns CVAC or BNTX?
BioNTech SE has a net margin of -5832.47% compared to CureVac NV's net margin of -1.89%. CureVac NV's return on equity of 20.55% beat BioNTech SE's return on equity of -3.01%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV91.57% $1.41 $1.1B BNTXBioNTech SE90.24% -$0.14 $22B -
What do Analysts Say About CVAC or BNTX?
CureVac NV has a consensus price target of $5.31, signalling upside risk potential of 14.28%. On the other hand BioNTech SE has an analysts' consensus of $139.76 which suggests that it could grow by 26.57%. Given that BioNTech SE has higher upside potential than CureVac NV, analysts believe BioNTech SE is more attractive than CureVac NV.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV1 3 0 BNTXBioNTech SE14 5 0 -
Is CVAC or BNTX More Risky?
CureVac NV has a beta of 1.877, which suggesting that the stock is 87.704% more volatile than S&P 500. In comparison BioNTech SE has a beta of 1.488, suggesting its more volatile than the S&P 500 by 48.755%.
-
Which is a Better Dividend Stock CVAC or BNTX?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or BNTX?
CureVac NV quarterly revenues are $63.3M, which are smaller than BioNTech SE quarterly revenues of $1.8B. CureVac NV's net income of $319.3M is higher than BioNTech SE's net income of -$33.5M. Notably, CureVac NV's price-to-earnings ratio is 6.52x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 12.94x versus 7.51x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV12.94x 6.52x $63.3M $319.3M BNTXBioNTech SE7.51x 191.55x $1.8B -$33.5M
-
Which has Higher Returns CVAC or IFRX?
InflaRx NV has a net margin of -5832.47% compared to CureVac NV's net margin of -51538.49%. CureVac NV's return on equity of 20.55% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV91.57% $1.41 $1.1B IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About CVAC or IFRX?
CureVac NV has a consensus price target of $5.31, signalling upside risk potential of 14.28%. On the other hand InflaRx NV has an analysts' consensus of $10.46 which suggests that it could grow by 1098.21%. Given that InflaRx NV has higher upside potential than CureVac NV, analysts believe InflaRx NV is more attractive than CureVac NV.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV1 3 0 IFRXInflaRx NV5 2 0 -
Is CVAC or IFRX More Risky?
CureVac NV has a beta of 1.877, which suggesting that the stock is 87.704% more volatile than S&P 500. In comparison InflaRx NV has a beta of 1.457, suggesting its more volatile than the S&P 500 by 45.659%.
-
Which is a Better Dividend Stock CVAC or IFRX?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or IFRX?
CureVac NV quarterly revenues are $63.3M, which are larger than InflaRx NV quarterly revenues of $27.8K. CureVac NV's net income of $319.3M is higher than InflaRx NV's net income of -$14.3M. Notably, CureVac NV's price-to-earnings ratio is 6.52x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 12.94x versus 269.55x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV12.94x 6.52x $63.3M $319.3M IFRXInflaRx NV269.55x -- $27.8K -$14.3M
-
Which has Higher Returns CVAC or IMTX?
Immatics NV has a net margin of -5832.47% compared to CureVac NV's net margin of -974.45%. CureVac NV's return on equity of 20.55% beat Immatics NV's return on equity of -25.21%.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV91.57% $1.41 $1.1B IMTXImmatics NV-- -$0.49 $508.8M -
What do Analysts Say About CVAC or IMTX?
CureVac NV has a consensus price target of $5.31, signalling upside risk potential of 14.28%. On the other hand Immatics NV has an analysts' consensus of $19.13 which suggests that it could grow by 85.68%. Given that Immatics NV has higher upside potential than CureVac NV, analysts believe Immatics NV is more attractive than CureVac NV.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV1 3 0 IMTXImmatics NV9 0 0 -
Is CVAC or IMTX More Risky?
CureVac NV has a beta of 1.877, which suggesting that the stock is 87.704% more volatile than S&P 500. In comparison Immatics NV has a beta of 1.359, suggesting its more volatile than the S&P 500 by 35.865%.
-
Which is a Better Dividend Stock CVAC or IMTX?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or IMTX?
CureVac NV quarterly revenues are $63.3M, which are larger than Immatics NV quarterly revenues of $6.1M. CureVac NV's net income of $319.3M is higher than Immatics NV's net income of -$59.1M. Notably, CureVac NV's price-to-earnings ratio is 6.52x while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 12.94x versus 13.76x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV12.94x 6.52x $63.3M $319.3M IMTXImmatics NV13.76x 42.21x $6.1M -$59.1M
-
Which has Higher Returns CVAC or MDGEF?
Medigene AG has a net margin of -5832.47% compared to CureVac NV's net margin of --. CureVac NV's return on equity of 20.55% beat Medigene AG's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CVACCureVac NV91.57% $1.41 $1.1B MDGEFMedigene AG-- -- -- -
What do Analysts Say About CVAC or MDGEF?
CureVac NV has a consensus price target of $5.31, signalling upside risk potential of 14.28%. On the other hand Medigene AG has an analysts' consensus of -- which suggests that it could fall by --. Given that CureVac NV has higher upside potential than Medigene AG, analysts believe CureVac NV is more attractive than Medigene AG.
Company Buy Ratings Hold Ratings Sell Ratings CVACCureVac NV1 3 0 MDGEFMedigene AG0 0 0 -
Is CVAC or MDGEF More Risky?
CureVac NV has a beta of 1.877, which suggesting that the stock is 87.704% more volatile than S&P 500. In comparison Medigene AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CVAC or MDGEF?
CureVac NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medigene AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CureVac NV pays -- of its earnings as a dividend. Medigene AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVAC or MDGEF?
CureVac NV quarterly revenues are $63.3M, which are larger than Medigene AG quarterly revenues of --. CureVac NV's net income of $319.3M is higher than Medigene AG's net income of --. Notably, CureVac NV's price-to-earnings ratio is 6.52x while Medigene AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CureVac NV is 12.94x versus -- for Medigene AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVACCureVac NV12.94x 6.52x $63.3M $319.3M MDGEFMedigene AG-- -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
46
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 21.87% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is up 3.81% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 16.79% over the past day.
